{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T07:18:23Z","timestamp":1769152703017,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s10072-021-05861-4","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T12:04:03Z","timestamp":1641816243000},"page":"3305-3312","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Patient-reported outcomes of migraine treatment with erenumab: results from a national patient survey"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7508-0971","authenticated-orcid":false,"given":"Aust\u0117ja","family":"Dapkut\u0117","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jurgita","family":"Vainauskien\u0117","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Ryli\u0161kien\u0117","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,10]]},"reference":[{"issue":"Suppl 1","key":"5861_CR1","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1016\/j.pain.2013.07.021","volume":"154","author":"R Noseda","year":"2013","unstructured":"Noseda R, Burstein R (2013) Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain. Pain 154(Suppl 1):S44-53. https:\/\/doi.org\/10.1016\/j.pain.2013.07.021","journal-title":"Pain"},{"key":"5861_CR2","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/head.12055","volume":"53","author":"AM Blumenfeld","year":"2013","unstructured":"Blumenfeld AM, Bloudek LM, Becker WJ et al (2013) Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache 53:644\u2013655. https:\/\/doi.org\/10.1111\/head.12055","journal-title":"Headache"},{"key":"5861_CR3","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0333102416678382","volume":"37","author":"Z Hepp","year":"2017","unstructured":"Hepp Z, Dodick DW, Varon SF et al (2017) Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia 37:470\u2013485. https:\/\/doi.org\/10.1177\/0333102416678382","journal-title":"Cephalalgia"},{"key":"5861_CR4","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1177\/0333102414547138","volume":"35","author":"Z Hepp","year":"2015","unstructured":"Hepp Z, Dodick DW, Varon SF et al (2015) Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia Int J Headache 35:478\u2013488. https:\/\/doi.org\/10.1177\/0333102414547138","journal-title":"Cephalalgia Int J Headache"},{"key":"5861_CR5","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s10194-019-0998-8","volume":"20","author":"R Cowan","year":"2019","unstructured":"Cowan R, Cohen JM, Rosenman E, Iyer R (2019) Physician and patient preferences for dosing options in migraine prevention. J Headache Pain 20:50. https:\/\/doi.org\/10.1186\/s10194-019-0998-8","journal-title":"J Headache Pain"},{"key":"5861_CR6","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/j.1526-4610.2006.00429.x","volume":"46","author":"TD Rozen","year":"2006","unstructured":"Rozen TD (2006) Migraine prevention: what patients want from medication and their physicians (a headache specialty clinic perspective). Headache 46:750\u2013753. https:\/\/doi.org\/10.1111\/j.1526-4610.2006.00429.x","journal-title":"Headache"},{"issue":"Suppl 1","key":"5861_CR7","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1111\/j.1526-4610.2008.01336.x","volume":"49","author":"ME Bigal","year":"2009","unstructured":"Bigal ME, Ferrari M, Silberstein SD et al (2009) Migraine in the triptan era: lessons from epidemiology, pathophysiology, and clinical science. Headache 49(Suppl 1):S21-33. https:\/\/doi.org\/10.1111\/j.1526-4610.2008.01336.x","journal-title":"Headache"},{"key":"5861_CR8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/head.13302","volume":"58","author":"U Reuter","year":"2018","unstructured":"Reuter U (2018) A review of monoclonal antibody therapies and other preventative treatments in migraine. Headache J Head Face Pain 58:48\u201359. https:\/\/doi.org\/10.1111\/head.13302","journal-title":"Headache J Head Face Pain"},{"key":"5861_CR9","unstructured":"European Medicines Agency (2018) Aimovig. In: Eur. Med. Agency. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/aimovig. Accessed 15 Apr 2020"},{"key":"5861_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s10194-020-01102-9","volume":"21","author":"R Ornello","year":"2020","unstructured":"Ornello R, Casalena A, Frattale I et al (2020) Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain 21:32. https:\/\/doi.org\/10.1186\/s10194-020-01102-9","journal-title":"J Headache Pain"},{"key":"5861_CR11","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s10072-020-04667-0","volume":"41","author":"E Matteo","year":"2020","unstructured":"Matteo E, Favoni V, Pascazio A et al (2020) Erenumab in 159 high frequency and chronic migraine patients: real-life results from the Bologna Headache Center. Neurol Sci 41:483\u2013484. https:\/\/doi.org\/10.1007\/s10072-020-04667-0","journal-title":"Neurol Sci"},{"key":"5861_CR12","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1111\/head.13968","volume":"60","author":"S Cheng","year":"2020","unstructured":"Cheng S, Jenkins B, Limberg N, Hutton E (2020) Erenumab in chronic migraine: an Australian experience. Headache J Head Face Pain 60:2555\u20132562. https:\/\/doi.org\/10.1111\/head.13968","journal-title":"Headache J Head Face Pain"},{"key":"5861_CR13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s10194-020-01127-0","volume":"21","author":"G Lambru","year":"2020","unstructured":"Lambru G, Hill B, Murphy M et al (2020) A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain 21:61. https:\/\/doi.org\/10.1186\/s10194-020-01127-0","journal-title":"J Headache Pain"},{"key":"5861_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s10194-020-01214-2","volume":"22","author":"J Talbot","year":"2021","unstructured":"Talbot J, Stuckey R, Crawford L et al (2021) Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment\u2013real world outcomes. J Headache Pain 22:5. https:\/\/doi.org\/10.1186\/s10194-020-01214-2","journal-title":"J Headache Pain"},{"key":"5861_CR15","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s10072-020-04677-y","volume":"41","author":"A Ranieri","year":"2020","unstructured":"Ranieri A, Alfieri G, Napolitano M et al (2020) One year experience with erenumab: real-life data in 30 consecutive patients. Neurol Sci 41:505\u2013506. https:\/\/doi.org\/10.1007\/s10072-020-04677-y","journal-title":"Neurol Sci"},{"key":"5861_CR16","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/j.1526-4610.2007.00757.x","volume":"47","author":"MFP Peres","year":"2007","unstructured":"Peres MFP, Silberstein S, Moreira F et al (2007) Patients\u2019 preference for migraine preventive therapy. Headache 47:540\u2013545. https:\/\/doi.org\/10.1111\/j.1526-4610.2007.00757.x","journal-title":"Headache"},{"key":"5861_CR17","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","volume":"16","author":"S Tepper","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U et al (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16:425\u2013434. https:\/\/doi.org\/10.1016\/S1474-4422(17)30083-2","journal-title":"Lancet Neurol"},{"key":"5861_CR18","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S1474-4422(16)00019-3","volume":"15","author":"H Sun","year":"2016","unstructured":"Sun H, Dodick DW, Silberstein S et al (2016) Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 15:382\u2013390. https:\/\/doi.org\/10.1016\/S1474-4422(16)00019-3","journal-title":"Lancet Neurol"},{"key":"5861_CR19","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y et al (2017) A controlled trial of erenumab for episodic migraine. N Engl J Med 377:2123\u20132132. https:\/\/doi.org\/10.1056\/NEJMoa1705848","journal-title":"N Engl J Med"},{"key":"5861_CR20","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","volume":"38","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Ashina M, Brandes JL et al (2018) ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 38:1026\u20131037. https:\/\/doi.org\/10.1177\/0333102418759786","journal-title":"Cephalalgia"},{"key":"5861_CR21","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","volume":"392","author":"U Reuter","year":"2018","unstructured":"Reuter U, Goadsby PJ, Lanteri-Minet M et al (2018) Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet 392:2280\u20132287. https:\/\/doi.org\/10.1016\/S0140-6736(18)32534-0","journal-title":"Lancet"},{"key":"5861_CR22","unstructured":"Profilaktinis migrenos gydymas erenumabu (2020). Neurologijos Seminarai. http:\/\/www.neuroseminarai.lt\/profilaktinis-migrenos-gydymas-erenumabu\/. Accessed 18 Jun 2021"},{"key":"5861_CR23","doi-asserted-by":"publisher","unstructured":"Raffaelli B, Kalantzis R, Mecklenburg J, et al (2020) Erenumab in chronic migraine patients who previously failed five first-line oral prophylactics and onabotulinumtoxinA: a dual-center retrospective observational study. Front Neurol 11. https:\/\/doi.org\/10.3389\/fneur.2020.00417","DOI":"10.3389\/fneur.2020.00417"},{"key":"5861_CR24","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s10194-020-01143-0","volume":"21","author":"A Russo","year":"2020","unstructured":"Russo A, Silvestro M, Scotto di Clemente F et al (2020) Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience. J Headache Pain 21:69. https:\/\/doi.org\/10.1186\/s10194-020-01143-0","journal-title":"J Headache Pain"},{"key":"5861_CR25","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1111\/head.13951","volume":"60","author":"J Robblee","year":"2020","unstructured":"Robblee J, Devick KL, Mendez N et al (2020) Real-world patient experience with erenumab for the preventive treatment of migraine. Headache 60:2014\u20132025. https:\/\/doi.org\/10.1111\/head.13951","journal-title":"Headache"},{"key":"5861_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-021-05105-5","author":"MM Cainazzo","year":"2021","unstructured":"Cainazzo MM, Baraldi C, Ferrari A et al (2021) Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study. Neurol Sci. https:\/\/doi.org\/10.1007\/s10072-021-05105-5","journal-title":"Neurol Sci"},{"key":"5861_CR27","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1177\/0333102419888222","volume":"39","author":"M Ashina","year":"2019","unstructured":"Ashina M, Kudrow D, Reuter U et al (2019) Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: a pooled analysis of four placebo-controlled trials with long-term extensions. Cephalalgia 39:1798\u20131808. https:\/\/doi.org\/10.1177\/0333102419888222","journal-title":"Cephalalgia"},{"key":"5861_CR28","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/head.13316","volume":"58","author":"C Depre","year":"2018","unstructured":"Depre C, Antalik L, Starling A et al (2018) A randomized, double-blind, placebo-controlled study to evaluate the effect of erenumab on exercise time during a treadmill test in patients with stable angina. Headache 58:715\u2013723. https:\/\/doi.org\/10.1111\/head.13316","journal-title":"Headache"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-021-05861-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-021-05861-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-021-05861-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T09:17:33Z","timestamp":1650446253000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-021-05861-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,10]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["5861"],"URL":"https:\/\/doi.org\/10.1007\/s10072-021-05861-4","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,10]]},"assertion":[{"value":"13 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The participation in this anonymous survey was voluntary and a confirmation of informed consent from each participant was obtained as a required clause in the survey.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}